Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart (Q33392979)

26 July 2017

title

Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart (English)

1 reference

26 July 2017

Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart (English)

1 reference

https://api.crossref.org/works/10.1016/J.YJMCC.2010.11.009

3 September 2024

main subject

translational medicine

1 reference

Timothy A. McKinsey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21108947

3 September 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21108947

3 September 2024

publication date

23 November 2010

1 reference

full work available at URL

26 July 2017

https://api.elsevier.com/content/article/PII:S0022282810004414?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.YJMCC.2010.11.009

https://api.elsevier.com/content/article/PII:S0022282810004414?httpAccept=text/plain

3 September 2024

1 reference

https://api.crossref.org/works/10.1016/J.YJMCC.2010.11.009

Journal of Molecular and Cellular Cardiology

3 September 2024

published in

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

491-496

1 reference

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Lysine acetylation: codified crosstalk with other posttranslational modifications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Chemical phylogenetics of histone deacetylases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Prognostic significance of left ventricular mass change during treatment of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Left ventricular hypertrophy: the next treatable, silent killer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Histone deacetylase is a target of valproic acid-mediated cellular differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Structure-function studies for the panacea, valproic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Inhibition of histone deacetylase on ventricular remodeling in infarcted rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Krüppel-like factor 4 regulates pressure-induced cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Subtype selective substrates for histone deacetylases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Treatment of heart failure with preserved ejection fraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Clinical studies of histone deacetylase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Chronic oral administration of CI-994: a phase 1 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Anticancer activities of histone deacetylase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

Effect of serum triiodothyronine on regulation of cardiac gene expression: role of histone acetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.11.009

7 January 2021

Identifiers

1 reference

26 July 2017

1 reference